The stock of Intellia Therapeutics Inc (NTLA) has gone down by -7.21% for the week, with a -10.16% drop in the past month and a -23.04% drop in the past quarter. The volatility ratio for the week is 5.04%, and the volatility levels for the past 30 days are 4.81% for NTLA. The simple moving average for the past 20 days is -12.91% for NTLA’s stock, with a -28.26% simple moving average for the past 200 days.
Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?
Moreover, the 36-month beta value for NTLA is 1.78. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NTLA is 99.78M and currently, short sellers hold a 14.79% of that float. On October 08, 2024, NTLA’s average trading volume was 1.44M shares.
NTLA) stock’s latest price update
The stock of Intellia Therapeutics Inc (NASDAQ: NTLA) has decreased by -0.14 when compared to last closing price of 17.84. Despite this, the company has experienced a -7.21% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-07 that CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the initiation of HAELO, a global, pivotal Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is a wholly owned investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for this potentially life-threatening disease. Patient screening is active following Intellia’s successful end-of-Phase 2 meeting and submission of an Investigational New Drug Application amendment to the U.S. Food and Drug Administration (FDA).
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with Goldman repeating the rating for NTLA by listing it as a “Neutral.” The predicted price for NTLA in the upcoming period, according to Goldman is $32 based on the research report published on February 23, 2024 of the current year 2024.
Canaccord Genuity gave a rating of “Buy” to NTLA, setting the target price at $66 in the report published on April 13th of the previous year.
NTLA Trading at -18.01% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.91% of loss for the given period.
Volatility was left at 4.81%, however, over the last 30 days, the volatility rate increased by 5.04%, as shares sank -11.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.76% lower at present.
During the last 5 trading sessions, NTLA fell by -7.06%, which changed the moving average for the period of 200-days by -39.75% in comparison to the 20-day moving average, which settled at $20.46. In addition, Intellia Therapeutics Inc saw -41.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NTLA starting from Dube Michael P, who sale 2,012 shares at the price of $19.01 back on Oct 02 ’24. After this action, Dube Michael P now owns 47,012 shares of Intellia Therapeutics Inc, valued at $38,248 using the latest closing price.
Clark Eliana, the EVP, Chief Technical Officer of Intellia Therapeutics Inc, sale 405 shares at $22.93 during a trade that took place back on Jul 01 ’24, which means that Clark Eliana is holding 71,470 shares at $9,287 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -11.4 for the present operating margin
- 0.79 for the gross margin
The net margin for Intellia Therapeutics Inc stands at -11.07. The total capital return value is set at -0.48. Equity return is now at value -49.02, with -40.46 for asset returns.
Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.51. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -59.33.
Currently, EBITDA for the company is -506.21 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 38.89. The receivables turnover for the company is 3.73for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.21.
Conclusion
To wrap up, the performance of Intellia Therapeutics Inc (NTLA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
